STOCK TITAN

Stonepine Group (NASDAQ: CRIS) reports 4.03M shares, 9.9% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

CURIS INC filed a Schedule 13G reporting a shared beneficial ownership position of 4,025,992 shares, equal to 9.9% of the outstanding common stock. The reporting persons are Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico, filing jointly.

The filing states the calculation is based on 39,978,693 shares outstanding as of March 20, 2026. It also discloses warrants to acquire 10,000,002 shares that are subject to a 9.99% beneficial ownership limitation. Voting and dispositive power are reported as shared for the 4,025,992 shares; sole voting/dispositive power is reported as 0 for each reporting person.

Positive

  • None.

Negative

  • None.

Insights

Stonepine reports a near-10% shared stake with warrants limited to 9.99%.

The filing shows 4,025,992 shares of shared beneficial ownership and references warrants for 10,000,002 shares subject to a 9.99% ownership cap. This structure indicates the reported percentage reflects the exercise limit rather than unconstrained conversion.

Future disclosures may clarify whether warrant exercises or further conversions will be pursued; any changes would be visible in subsequent ownership amendments or Form 4/5 filings.

Filing signals a meaningful passive position by an investment vehicle rather than an individual controlling block.

The Partnership holds the shares for investors; the filing notes the Partnership "has the right to receive or the power to direct the receipt of dividends" for holdings above 5%. Reported shared voting/dispositive power is 4,025,992 across the named entities.

Stake size and warrant mechanics are the principal items to watch in follow-up filings for potential conversion, sales, or changes in voting power.






231269309

(CUSIP Number)
03/17/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 3,704,462 shares of Common Stock, and (2) warrants to acquire 10,000,002 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 39,978,693 shares of Common Stock, outstanding as of March 20, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 3,704,462 shares of Common Stock, and (2) warrants to acquire 10,000,002 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 39,978,693 shares of Common Stock, outstanding as of March 20, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 3,704,462 shares of Common Stock, and (2) warrants to acquire 10,000,002 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 39,978,693 shares of Common Stock, outstanding as of March 20, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities beneficially owned by the reporting persons consist of (1) 3,704,462 shares of Common Stock, and (2) warrants to acquire 10,000,002 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. The percentage reported herein is calculated based on 39,978,693 shares of Common Stock, outstanding as of March 20, 2026, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2025.


SCHEDULE 13G



Stonepine Capital Management, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:03/27/2026
Stonepine Capital, L.P.
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
Date:03/27/2026
Stonepine GP, LLC
Signature:/s/ Jon M. Plexico
Name/Title:Managing Member
Date:03/27/2026
Jon M. Plexico
Signature:/s/ Jon M. Plexico
Name/Title:Reporting person
Date:03/27/2026
Exhibit Information

EXHIBIT 99 - AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

FAQ

What stake does Stonepine report in CURIS (CRIS)?

Stonepine reports shared beneficial ownership of 4,025,992 shares, representing 9.9% of common stock based on 39,978,693 shares outstanding as of March 20, 2026. The position is reported as shared voting and dispositive power.

Does the filing include convertible instruments or warrants?

Yes. The filing discloses warrants to acquire 10,000,002 shares, but those warrants are subject to a 9.99% beneficial ownership limitation that constrains conversion impact on ownership percentages.

Who are the reporting persons on the Schedule 13G?

The filing lists Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico as the reporting persons, filing jointly while disclaiming group membership and certain direct beneficial ownership claims.

How was the percent ownership calculated?

The percent is calculated using 39,978,693 shares outstanding as of March 20, 2026, as cited from the issuer's Form 10-K for the fiscal year ended December 31, 2025, producing the reported 9.9% figure.

Does Stonepine report sole voting or dispositive power?

No. For each reporting person the filing reports 0 shares of sole voting or sole dispositive power and 4,025,992 shares of shared voting and shared dispositive power.
Curis

NASDAQ:CRIS

View CRIS Stock Overview

CRIS Rankings

CRIS Latest News

CRIS Latest SEC Filings

CRIS Stock Data

23.19M
12.79M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
LEXINGTON